神经肌肉疾病相关睡眠呼吸障碍诊治专家共识
中华医学会呼吸病学分会睡眠呼吸障碍学组组织多学科专家制定本共识,针对神经肌肉疾病相关睡眠呼吸障碍的流行病学、临床表现、诊断评估和治疗形成3条陈述及5条推荐意见,强调早期识别并启动无创通气、氧疗、呼吸康复等干预,以规范临床诊治。
要点
- 最易合并睡眠呼吸障碍的神经肌肉疾病包括重症肌无力、肌萎缩侧索硬化等。
- 疑似睡眠呼吸障碍应评估症状并积极行睡眠监测及无创CO2监测。
- PSG下无创正压通气滴定是确定有效治疗参数的标准方法。
核心结论
- 神经肌肉疾病易合并睡眠呼吸障碍,需早期识别并启动无创通气、氧疗、呼吸康复等治疗。
- 本共识形成3条陈述及5条推荐意见,为神经肌肉疾病相关睡眠呼吸障碍的诊治提供规范化建议。
研究设计与样本
- 由中华医学会呼吸病学分会睡眠呼吸障碍学组组织多学科专家制定。
- 参考国内外最新研究进展和指南共识,结合国内临床诊治实践经验。
主要发现
- 最易合并睡眠呼吸障碍的神经肌肉疾病包括重症肌无力(1A)、肌萎缩侧索硬化(2B)、脊髓灰质炎后遗症(2B)、强直性肌营养不良(2B)、周围神经病变(2C)、代谢性肌病等。
- 神经肌肉疾病患者常同时出现或序贯发生多种类型睡眠呼吸障碍,合并OSA最常见,不同亚型有各自临床特点(1A)。
- 神经肌肉疾病易伴有CSA,临床表现与疾病类型、病程及严重程度相关(1A)。
关键数值与推荐
- 推荐意见1:神经肌肉疾病所致CO2潴留/低氧进一步加重时,注意是否合并睡眠相关肺泡低通气症/低氧血症(1A)。
- 推荐意见2:疑似合并睡眠呼吸障碍应评估相关症状并积极行睡眠监测、无创CO2监测(1A);高度怀疑但便携式监测阴性应行PSG(1A)。
- 推荐意见3:PSG下无创正压通气滴定是确定有效治疗参数的标准方法(1A);合并OSA滴定遵循AASM指南(1A);伴CSA或陈-施呼吸推荐ST模式BPAP(1A),不能耐受或伴严重陈-施呼吸、心衰应用ASV(2B);合并睡眠相关肺泡低通气使用BPAP或VAPS并监测CO2(1A);合并「伪中枢事件」首选具有备用频率的BPAP(1A)。
- 推荐意见4:不推荐单独氧疗(2D),无创通气不能有效纠正低氧血症时辅以氧疗并监测CO2(2C);膈肌起搏不作为ALS呼吸衰竭常规治疗(2B);经静脉膈神经刺激尚未应用于神经肌肉疾病引起的CSA(2D);呼吸康复可能改善部分患者呼吸肌力量(2B);REM相关肺泡低通气可应用普罗替林,日间嗜睡可应用哌醋甲酯和莫达非尼(2C)。
- 推荐意见5:神经肌肉疾病合并睡眠呼吸障碍是慢性疾病,需以患者为中心的个体化教育和长期随访管理(1A)。
临床怎么用
- 对神经肌肉疾病患者应主动筛查睡眠呼吸障碍症状,疑似时积极行睡眠监测及无创CO2监测。
- 确诊后根据类型选择NPPV等治疗,PSG下滴定参数,合并CSA或陈-施呼吸时选用ST模式BPAP。
- 避免单独氧疗,氧疗需在无创通气不能纠正低氧血症时辅以并监测CO2。
- 开展个体化教育和长期随访管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neuromuscular diseases are often accompanied by various types of sleep-related breathing disorders, which can exacerbate the underlying condition and are associated with a poor prognosis. Early identification is essential, and interventions such as non-invasive ventilation, oxygen therapy, and respiratory rehabilitation should be initiated promptly to mitigate disease progression and improve outcomes. Nevertheless, the rates of missed and misdiagnosed cases remain common in clinical practice. Currently, there are no standardized guidelines for the diagnosis and treatment of sleep-disordered breathing related to neuromuscular diseases in China. Therefore, based on the latest domestic and international research progress, and combined with domestic clinical diagnosis and treatment experience, the Sleep Disorder Group of Chinese Thoracic Society has brought together multidisciplinary experts to develop this expert consensus. This consensus provides a comprehensive overview of the epidemiology, clinical manifestations, diagnostic approaches, assessment strategies, and treatment of sleep-disordered breathing related to neuromuscular diseases. It formulates evidence-based recommendations to guide clinical practice, with the aim of providing standardized recommendations for their diagnosis and management.Statement 1: The neuromuscular disorders that are most frequently associated with sleep-disordered breathing include: myasthenia gravis (1A), amyotrophic lateral sclerosis (2B), post-polio syndrome (2B), myotonic dystrophy (2B), peripheral neuropathies (2C), and metabolic myopathies, among other neuromuscular conditions.Statement 2: Patients with neuromuscular disorders frequently develop multiple types of sleep-disordered breathing concurrently or sequentially, with obstructive sleep apnea (OSA) being the most prevalent manifestation. Distinct clinical manifestations of OSA are observed across different neuromuscular disease subtypes (1A).Statement 3: Neuromuscular disorders predispose to central sleep apnea (CSA), with clinical manifestations varying significantly across disease subtypes, stages of progression, and severity levels (1A).Recommendation 1: In patients with neuromuscular disorders exhibiting progressive hypercapnia or worsening hypoxemia, clinicians should investigate potential comorbid nocturnal alveolar hypoventilation and/or sleep-associated hypoxemia (1A).Recommendation 2: When sleep-disordered breathing is suspected, patients with neuromuscular disorders should be evaluated for symptoms of sleep-disordered breathing. Meanwhile, sleep monitoring, non-invasive CO2 monitoring, and related examinations should be actively performed according to the actual situation (1A). A polysomnography should be performed when there is a high clinical suspicion of sleep-disordered breathing but a negative result on a portable sleep monitor (1A).Recommendation 3: (1) Noninvasive positive pressure ventilation (NPPV) titration under polysomnography is the standard method to determine the effective treatment parameters for neuromuscular diseases with sleep-disordered breathing (1A). (2) Positive airway pressure titration in OSA patients with neuromuscular diseases should follow American Academy of Sleep Medicine (AASM) guidelines (1A). (3) For neuromuscular disorders with CSA or Cheyne-Stokes respiration, bi-level positive airway pressure (BPAP) with ST pattern is recommended (1A); When BPAP is not tolerated or accompanied by severe Cheyne-Stokes respiratory and heart failure in patients, adaptive support ventilation (ASV) should be used (2B). (4) Patients with neuromuscular disease and sleep-related alveolar hypoventilation should be treated with BPAP or variable assurance pressure support (VAPS) (1A). (5) BPAP with alternate frequency is preferred for neuromuscular disorders with "pseudo-central events" (1A).Recommendation 4: Oxygen therapy alone is not recommended for neuromuscular disease patients combined with sleep-disordered breathing (2D). Oxygen therapy with monitoring of CO2 level is recommended when non-invasive ventilation therapy cannot effectively correct hypoxemia (2C). Diaphragmatic pacing should not be routinely used in amyotrophic lateral sclerosis patients with respiratory failure (2B). Transvenous phrenic nerve stimulation is not currently applied to CSA caused by neuromuscular disorders (2D). Respiratory rehabilitation may improve respiratory muscle strength in a subset of patients with neuromuscular disorders (2B). Protiline can be used for REM-associated alveolar hypoventilation, and daytime sleepiness could be addressed with methylphenidate and modafinil (2C).Recommendation 5: Neuromuscular disease combined with sleep-disordered breathing is a chronic disease requiring patient-centered, individualized education and long-term follow-up management (1A). 神经肌肉疾病易合并不同类型的睡眠呼吸障碍,使患者病情加重、预后不佳,需要早期识别,并尽早启动无创通气、氧疗、呼吸康复等治疗,但是临床上漏诊率、误诊率高。目前国内尚无神经肌肉疾病相关睡眠呼吸障碍的诊疗规范,为此,中华医学会呼吸病学分会睡眠呼吸障碍学组组织相关多学科专家,参考国内外最新研究进展和指南共识,结合临床诊治实践经验,制定《神经肌肉疾病相关睡眠呼吸障碍诊治专家共识》,旨在对神经肌肉疾病相关睡眠呼吸障碍的流行病学、临床表现、诊断思路、评估和治疗进行详细阐释,共形成3条陈述及5条推荐意见,为神经肌肉疾病相关睡眠呼吸障碍诊断和治疗提供规范化建议。陈述1:最易合并睡眠呼吸障碍的神经肌肉疾病包括重症肌无力(1A)、肌萎缩侧索硬化(2B)、脊髓灰质炎后遗症(2B)、强直性肌营养不良(2B)、周围神经病变(2C)、代谢性肌病等。陈述2:神经肌肉疾病患者常同时出现或序贯发生多种类型的睡眠呼吸障碍,合并睡眠呼吸暂停(OSA)最常见,不同类型的神经肌肉疾病合并OSA时有各自的临床特点(1A)。陈述3:神经肌肉疾病易伴有中枢性睡眠呼吸暂停(CSA),其临床表现与疾病的类型、病程及严重程度相关(1A)。推荐意见1:当神经肌肉疾病所致CO2潴留/低氧进一步加重时,应注意是否合并睡眠相关肺泡低通气症/低氧血症(1A)。推荐意见2:神经肌肉疾病患者疑似合并睡眠呼吸障碍时,应评估睡眠呼吸障碍相关症状,并根据实际情况积极进行睡眠呼吸监测、无创CO2监测和相关检查(1A)。如果临床高度怀疑有睡眠呼吸障碍但便携式睡眠监测结果为阴性,应进行全面的多导睡眠监测(PSG)检查(1A)。推荐意见3:①神经肌肉疾病合并睡眠呼吸障碍,PSG下进行无创正压通气滴定是确定有效治疗参数的标准方法(1A);②神经肌肉疾病合并OSA,滴定应遵循美国睡眠医学会(AASM)关于OSA患者气道正压通气滴定的临床指南(1A);③神经肌肉疾病伴有CSA或陈-施呼吸时,推荐使用带有ST模式的双水平气道正压通气(BPAP)(1A);患者不能耐受BPAP时或伴有严重的陈-施呼吸、心力衰竭,应用伺服通气设备(2B);④神经肌肉疾病合并睡眠相关肺泡低通气症使用BPAP或容量保证压力支持(VAPS)设备,同步监测CO2水平(1A);⑤神经肌肉疾病合并“伪中枢事件”,首选具有备用频率的BPAP(1A)。推荐意见4:神经肌肉疾病合并睡眠呼吸障碍时不推荐单独氧疗(2D),建议在无创通气治疗不能有效纠正低氧血症时辅以氧疗,建议同时监测CO2水平(2C)。膈肌起搏不作为肌萎缩侧索硬化症呼吸衰竭患者的常规治疗(2B)。经静脉膈神经刺激尚未应用于神经肌肉疾病引起的CSA(2D)。呼吸康复可能改善一部分神经肌肉疾病患者的呼吸肌力量(2B)。快速眼动(REM)睡眠期相关肺泡低通气可应用普罗替林,日间嗜睡可应用哌醋甲酯和莫达非尼(2C)。推荐意见5:神经肌肉疾病合并睡眠呼吸障碍是一种慢性疾病,需要开展以患者为中心的个体化教育,并进行长期随访管理(1A)。.
引用
- [Expert consensus on the diagnosis and treatment of sleep-disordered breathing related to neuromuscular diseases]. Zhonghua Jie He He Hu Xi Za Zhi. 2025. PMID: 40925732. doi:10.3760/cma.j.cn112147-20250614-00332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。